O ROURKE & COMPANY Inc Sells 59 Shares of Amgen Inc. (NASDAQ:AMGN)

O ROURKE & COMPANY Inc lessened its stake in Amgen Inc. (NASDAQ:AMGN) by 4.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,259 shares of the medical research company’s stock after selling 59 shares during the period. O ROURKE & COMPANY Inc’s holdings in Amgen were worth $358,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Diversified Trust Co lifted its stake in Amgen by 76.8% during the fourth quarter. Diversified Trust Co now owns 37,695 shares of the medical research company’s stock worth $10,857,000 after purchasing an additional 16,376 shares during the period. Provence Wealth Management Group increased its holdings in shares of Amgen by 11.9% during the fourth quarter. Provence Wealth Management Group now owns 1,445 shares of the medical research company’s stock worth $416,000 after buying an additional 154 shares in the last quarter. Kinsale Capital Group Inc. increased its holdings in shares of Amgen by 33.0% during the fourth quarter. Kinsale Capital Group Inc. now owns 11,348 shares of the medical research company’s stock worth $3,269,000 after buying an additional 2,814 shares in the last quarter. Global Wealth Management Investment Advisory Inc. increased its holdings in shares of Amgen by 2.4% during the fourth quarter. Global Wealth Management Investment Advisory Inc. now owns 4,733 shares of the medical research company’s stock worth $1,363,000 after buying an additional 109 shares in the last quarter. Finally, Traynor Capital Management Inc. increased its holdings in shares of Amgen by 9.5% during the fourth quarter. Traynor Capital Management Inc. now owns 18,941 shares of the medical research company’s stock worth $5,455,000 after buying an additional 1,650 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on AMGN shares. UBS Group raised their price objective on shares of Amgen from $284.00 to $307.00 and gave the stock a “neutral” rating in a report on Friday, May 3rd. TD Cowen dropped their price objective on shares of Amgen from $370.00 to $360.00 and set a “buy” rating for the company in a report on Wednesday, April 17th. Royal Bank of Canada raised their price target on shares of Amgen from $328.00 to $332.00 and gave the company an “outperform” rating in a report on Friday, June 14th. Morgan Stanley raised their price target on shares of Amgen from $271.00 to $310.00 and gave the company an “equal weight” rating in a report on Friday, May 3rd. Finally, BMO Capital Markets raised their price target on shares of Amgen from $336.00 to $355.00 and gave the company an “outperform” rating in a report on Friday, May 3rd. Ten investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $307.35.

Insider Transactions at Amgen

In other news, SVP Nancy A. Grygiel sold 2,117 shares of Amgen stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $313.09, for a total transaction of $662,811.53. Following the transaction, the senior vice president now directly owns 9,883 shares of the company’s stock, valued at $3,094,268.47. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 0.69% of the company’s stock.

Amgen Trading Down 0.5 %

Shares of NASDAQ AMGN traded down $1.44 during midday trading on Monday, reaching $311.01. 1,768,651 shares of the stock were exchanged, compared to its average volume of 2,783,121. The business has a 50-day simple moving average of $301.56 and a two-hundred day simple moving average of $292.30. The company has a market capitalization of $166.84 billion, a price-to-earnings ratio of 44.36, a P/E/G ratio of 2.82 and a beta of 0.58. Amgen Inc. has a 12 month low of $218.44 and a 12 month high of $329.72. The company has a debt-to-equity ratio of 11.96, a current ratio of 1.42 and a quick ratio of 0.98.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, May 2nd. The medical research company reported $3.96 earnings per share for the quarter, topping analysts’ consensus estimates of $3.76 by $0.20. The company had revenue of $7.45 billion for the quarter, compared to analysts’ expectations of $7.45 billion. Amgen had a net margin of 12.74% and a return on equity of 156.21%. The business’s quarterly revenue was up 22.0% compared to the same quarter last year. During the same period last year, the firm posted $3.98 earnings per share. As a group, equities research analysts expect that Amgen Inc. will post 19.47 EPS for the current year.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.